By blocking HMG-CoA reductase, statins lower cholesterol biosynthesis and effectively treat dyslipidemia, which is commonly seen in patients with non-alcoholic fatty liver disease. This evidence concerns the gene HMGCR and metabolic dysfunction-associated steatotic liver disease.